TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026
TransCode Therapeutics' lead candidate TTX-MC138 will be featured in a poster at the ESMO Congress 2026 in Madrid on October 23. The poster highlights the Phase 1a clinical evaluation of TTX-MC138, a first-in-class antagomiR targeting miR-10b in patients with advanced solid tumors. No new data is disclosed in the release; the actual clinical results will be revealed at the presentation.
Key figures
- Drug Name
- TTX-MC138
- Phase Of Trial
- Phase 1a
- Poster id
- 1025P
- Presentation date
- October 23, 2026
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.